Literature DB >> 3932057

Severe withdrawal syndrome after substitution of a short-acting benzodiazepine for a long-acting benzodiazepine.

W S Bond, N J Berwish, B Swift.   

Abstract

A severe withdrawal syndrome occurred in a patient after oxazepam 10 mg bid was substituted for diazepam 5 mg bid. The onset of symptoms was consistent with the rate of decline of diazepam and its active metabolite, desmethyldiazepam. Reintroduction of diazepam produced prompt symptom remission. This report and others suggest the need for caution when substituting a short-acting drug for a long-acting one, even when usual doses of each are used. The chronic use of benzodiazepines for eight months or longer prior to substitution or withdrawal appears to place the patient at a higher risk of incurring withdrawal phenomena. Slow and careful tapering of drug is required in such patients to reduce the risk of withdrawal symptoms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932057     DOI: 10.1177/106002808501901010

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  2 in total

1.  Clinical aspects of therapeutic substitution.

Authors:  R A Levy
Journal:  Pharmacoeconomics       Date:  1992       Impact factor: 4.981

Review 2.  Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring.

Authors:  Anna Basińska-Szafrańska
Journal:  Eur J Clin Pharmacol       Date:  2021-01-03       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.